1-3 of 3
Anna van Troostenburg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Effectiveness of Idelalisib in Patients with Double-Refractory Follicular Lymphoma: A Pan-European Cohort of 242 Patients

Emmanuel Gyan, Maria Chiara Tisi, Francesco Merli, Luca Baldini, Francesco Di Raimondo, Santiago Mercadal, Benedetta Puccini, Elisabeth Vandenberghe, Ka Lung Wu, Anthony Boland, Rikisha Shah Gupta, Anna van Troostenburg, Carolyn Dunnill, Heribert Ramroth, Nishanthan Rajakumaraswamy, Gilles Salles
Journal: Blood
Blood (2021) 138 (Supplement 1): 1350.
https://doi.org/10.1182/blood-2021-146066
Published: 2021
Journal Articles

Safety Profile of Idelalisib in Patients with Refractory Follicular Lymphoma: Interim Analysis of a Noninterventional Study

Gilles Salles, MD PhD, Ka Lung Wu, MD PhD, Sofya Kovalchuk, MD, Santiago Mercadal, MD, Annalisa Chiarenza, MD PhD, Ruth Pettengell, MD, Elisabeth Vandenberghe, MD, Paolo Corradini, MD, Susana Carvalho, MD, Christophe De Belder, MSc, Rikisha Shah Gupta, MPH, Anna van Troostenburg, MD, Nishanthan Rajakumaraswamy, MD, Heribert Ramroth, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 48–50.
https://doi.org/10.1182/blood-2020-137607
Published: 2020
Journal Articles

Results from a Prospective Real World Study Show Strong Efficacy of Idelalisib in CLL, Including High-Risk CLL, and Provide Evidence That Pjp Prophylaxis Positively Impacts on Overall Survival

Manuela Hoechstetter, MD, Philipp Eissmann, Nike Hucke, Anna van Troostenburg, Heribert Ramroth, Wolfgang Knauf
Journal: Blood
Blood (2018) 132 (Supplement 1): 4428.
https://doi.org/10.1182/blood-2018-99-112843
Published: 2018